Bellicum to Report Second Quarter 2015 Financial Results on August 13, 2015
Conference Call and Webcast to Follow at
To access the call, participants should dial (855) 779-9069 (U.S. domestic) and (631) 485-4863 (international) at least 10 minutes prior to the start of the call, using Conference ID number 92664473. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will also be available for replay in the Investor and Media section of our website for at least two weeks following the call.
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR-T and TCR cell therapy, and dendritic cell vaccines. More information can be found at www.bellicum.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150806005027/en/
Source:
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso,
832-384-1116
Chief Financial Officer
amusso@bellicum.com
or
Media:
Brad
Miles, 646-513-3125
bmiles@bmccommunications.com
